Skip to main content
SpringerLink
Log in

Simple method to detect important epidermal growth factor receptor gene mutations with bronchoscopic specimens of lung cancer patients for gefitinib treatment

  • Original Research
  • Published:
Targeted Oncology Aims and scope Submit manuscript

Abstract

Recent studies have demonstrated that epidermal growth factor receptor (EGFR) mutations are a predictive molecular marker of tumor response to gefitinib treatment in non-small-cell lung cancer (NSCLC). Early studies of EGFR mutations have been analyzed by direct sequencing with surgically resected specimens. However, it is often difficult to obtain sufficient and tumor-enriched tissue specimens from inoperative NSCLC patients for mutation analysis. Therefore, we set out to develop a simple, sensitive and reliable method based on polymerase chain reaction (PCR) and restriction endonuclease treatment to detect important EGFR mutations for gefitinib treatment, including G719S, deletion or insertion in exons 19 and 20, T790M, L858R and L861Q using bronchoscopic specimens. Two hundred and eleven bronchoscopic samples cytologically diagnosed as malignant were analyzed and mutations detected from 60 patients (28.4%). The present assay could detect deletion in exon 19 and L858R mutations in the presence of at least 1% and 5% mutant cells, respectively, from a background of normal cells. Comparison of mutation detection between bronchoscopic and surgical specimens from 42 patients indicated that the sensitivity of this assay using bronchoscopic specimens was 95% (18/19) with a specificity of 100% (23/23). Furthermore, deletion variants in exon 19 could be distinguished by native polyacrylamide gel electrophoresis. Consequently, this simple, sensitive and reliable assay can provide important information pertaining to optimal therapeutic strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Haeder M, Rotsch M, Bepler G et al (1988) Epidermal growth factor receptor expression in human lung cancer cell lines. Cancer Res 48:1132–1136

    PubMed  CAS  Google Scholar 

  2. Hirsch FR, Varella-Garcia M, Bunn PA et al (2003) Epidermal growth factor receptor in non-small cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21:3798–3807

    Article  PubMed  CAS  Google Scholar 

  3. Pao W, Miller VA (2005) Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 23:2556–2568

    Article  PubMed  CAS  Google Scholar 

  4. Cohen S (1983) Purification of the receptor for epidermal growth factor from A-431 cells: its function as a tyrosyl kinase. Methods Enzymol 99:379–387

    Article  PubMed  CAS  Google Scholar 

  5. Jorissen RN, Walker F, Pouliot N et al (2003) Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 284:31–53

    Article  PubMed  CAS  Google Scholar 

  6. Wells A (1999) EGF receptor. Int J Biochem Cell Biol 31:637–643

    Article  PubMed  CAS  Google Scholar 

  7. Arteaga CL (2002) Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 29:3–9

    PubMed  CAS  Google Scholar 

  8. Fukuoka M, Yano S, Giaccone G et al (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the Ideal 1 trial). J Clin Oncol 21:2237–2246

    Article  PubMed  CAS  Google Scholar 

  9. Kris MG, Natale RB, Herbst RS et al (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290:2149–2158

    Article  PubMed  CAS  Google Scholar 

  10. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139

    Article  PubMed  CAS  Google Scholar 

  11. Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500

    Article  PubMed  CAS  Google Scholar 

  12. Pao W, Miller V, Zakowski M et al (2004) EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101:13306–13311

    Article  PubMed  CAS  Google Scholar 

  13. Mitsudomi T, Kosaka T, Endoh H et al (2005) Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23:2513–2520

    Article  PubMed  CAS  Google Scholar 

  14. Takano T, Ohe Y, Sakamoto H et al (2005) Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small cell lung cancer. J Clin Oncol 23:6829–6837

    Article  PubMed  CAS  Google Scholar 

  15. Han SW, Kim TY, Hwang PG et al (2005) Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small cell lung cancer patients treated with gefitinib. J Clin Oncol 23:2493–2501

    Article  PubMed  CAS  Google Scholar 

  16. Kosaka T, Yatabe Y, Endoh H et al (2004) Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64:8919–8923

    Article  PubMed  CAS  Google Scholar 

  17. Huang SF, Liu HP, Li LH et al (2004) High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 10:8195–8203

    Article  PubMed  CAS  Google Scholar 

  18. Shigematsu H, Lin L, Takahashi T et al (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97:339–346

    Article  PubMed  CAS  Google Scholar 

  19. Tokumo M, Toyooka S, Kiura K et al (2005) The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 11:1167–1173

    PubMed  CAS  Google Scholar 

  20. Marchetti A, Martella C, Felicioni L et al (2005) EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23:857–865

    Article  PubMed  CAS  Google Scholar 

  21. Kobayashi S, Boggon TJ, Dayaram T et al (2005) EGFR mutation and resistance of non-small cell lung cancer to gefitinib. N Engl J Med 352:786–792

    Article  PubMed  CAS  Google Scholar 

  22. Pao W, Miller VA, Politi KA et al (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:e73

    Article  PubMed  CAS  Google Scholar 

  23. Sasaki H, Endo K, Konishi A et al (2005) EGFR mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler. Clin Cancer Res 11:2924–2929

    Article  PubMed  CAS  Google Scholar 

  24. Ohnishi H, Ohtsuka K, Ooide A et al (2006) A simple and sensitive method for detecting major mutations within the tyrosine kinase domain of the epidermal growth factor receptor gene in non-small-cell lung carcinoma. Diagn Mol Pathol 15:101–108

    Article  PubMed  CAS  Google Scholar 

  25. Asano H, Toyooka S, Tokumo M et al (2006) Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. Clin Cancer Res 12:43–48

    Article  PubMed  CAS  Google Scholar 

  26. Nagai Y, Miyazawa H, Huqun et al (2005) Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 65:7276–7282

    Article  PubMed  CAS  Google Scholar 

  27. Janne PA, Borras AM, Kuang Y et al (2006) A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin Cancer Res 12:751–758

    Article  PubMed  Google Scholar 

  28. Oshita F, Matsukuma S, Yoshihara M et al (2006) Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancer. Br J Cancer 95:1070–1075

    Article  PubMed  CAS  Google Scholar 

  29. Nomoto K, Tsuta K, Takano T et al (2006) Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis. Am J Clin Pathol 126:608–615

    PubMed  CAS  Google Scholar 

  30. Kimura H, Kasahara K, Kawaishi M et al (2006) Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small cell lung cancer. Clin Cancer Res 12:3915–3921

    Article  PubMed  CAS  Google Scholar 

  31. Pao W, Wang TY, Riely GJ et al (2005) KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2:e17

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported in part by a grant-in-aid from the Japanese Ministry of Health, Labor and Welfare.

Author information

Authors and Affiliations

  1. Division of Molecular Diagnosis and Cancer Prevention, Saitama Cancer Center, 818 Komuro Ina, Kitaadachigun, Saitama, 362-0806, Japan

    Kiwamu Akagi

  2. Division of Thoracic Oncology, Saitama Cancer Center, 818 Komuro Ina, Kitaadachigun, Saitama, 362-0806, Japan

    Hiroshi Sakai, Junko Sudo, Yasuo Hommura, Futoshi Kurimoto, Hiroshi Komagata & Shuichi Yoneda

  3. Division of Thoracic Surgery, Saitama Cancer Center, 818 Komuro Ina, Kitaadachigun, Saitama, 362-0806, Japan

    Hirohiko Akiyama

Authors
  1. Kiwamu Akagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroshi Sakai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Junko Sudo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yasuo Hommura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Futoshi Kurimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hiroshi Komagata
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hirohiko Akiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shuichi Yoneda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kiwamu Akagi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Akagi, K., Sakai, H., Sudo, J. et al. Simple method to detect important epidermal growth factor receptor gene mutations with bronchoscopic specimens of lung cancer patients for gefitinib treatment. Targ Oncol 2, 145–151 (2007). https://doi.org/10.1007/s11523-007-0053-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11523-007-0053-6

Keywords

Search

Navigation